Roberta Duncan

Chief Strategy Officer at Arcturus Therapeutics

Speaker

Roberta Duncan is the Chief Strategy Officer at Arcturus Therapeutics and has been in the

biopharma industry for more than 26 years with experience from start-up and small biotech to

pharma and CROs. She is currently the Board Vice-Chair of the Alliance for mRNA Medicines

(AMM) and previously held the role of Vice President leading CSL’s enterprise-wide mRNA

Program. Roberta has led complex programs, driving profitable growth, enhancing

productivity, accelerating critical growth assets into the pipeline, leading revenue generating

products, and enabling commercial launch and market expansion. Roberta has an extensive

and diverse background across multiple therapeutic areas and business functions, inclusive

of strategy, business development, business planning and operations, governance, portfolio

and program management, program leadership, alliance management, R&D (including clinical

development, regulatory, clinical operations, R&D systems and compliance), and product

development. Her experience spans across industry-leading organizations such as CSL, Eli

Lilly, Bristol Myers Squibb, Shire Pharmaceuticals (acquired by Takeda), Trevi Therapeutics,

Kendle International (acquired by Syneos), and Quintiles (now IQVIA). Roberta earned her BA

in Biochemistry from New York University, as well as two MBAs in International Management

and Strategy from Krannert School of Management (Purdue University) and TiasNimbas

Business School (Tilburg University, The Netherlands).